The octapeptide angiotensin II (AngII) exerts a variety of cardiovascular effects through the activation of the AngII type 1 receptor (AT 1 ), a G protein-coupled receptor. The AT 1 receptor engages and activates several signaling pathways, including heterotrimeric G proteins G q and G 12 , as well as the extracellular signal-regulated kinases (ERK) 1/2 pathway. Additionally, following stimulation, barrestin is recruited to the AT 1 receptor, leading to receptor desensitization. It is increasingly recognized that specific ligands selectively bind and favor the activation of some signaling pathways over others, a concept termed ligand bias or functional selectivity. A better understanding of the molecular basis of functional selectivity may lead to the development of better therapeutics with fewer adverse effects. In the present study, we developed assays allowing the measurement of six different signaling modalities of the AT 1 receptor. Using a series of AngII peptide analogs that were modified in positions 1, 4, and 8, we sought to better characterize the molecular determinants of AngII that underlie functional selectivity of the AT 1 receptor in human embryonic kidney 293 cells. The results reveal that position 1 of AngII does not confer functional selectivity, whereas position 4 confers a bias toward ERK signaling over G q signaling, and position 8 confers a bias toward barrestin recruitment over ERK activation and G q signaling. Interestingly, the analogs modified in position 8 were also partial agonists of the protein kinase C (PKC)-dependent ERK pathway via atypical PKC isoforms PKCz and PKCi.
Introduction
The octapeptide hormone angiotensin II (AngII) is the active component of the renin-angiotensin system, responsible for controlling blood pressure and water retention via smooth muscle contraction and ion transport. It exerts a wide variety of physiologic effects, including vascular contraction, aldosterone secretion, neuronal activation, and cardiovascular cell growth and proliferation. Virtually all known physiologic effects of AngII are produced through the activation of the angiotensin II type 1 (AT 1 ) receptor, which belongs to the G protein-coupled receptor (GPCR) superfamily (de Gasparo et al., 2000) .
The AT 1 receptor interacts with the G protein G q/11 , which activates phospholipase C, which in turn generates inositol 1,4,5-trisphosphate (IP 3 ) and diacylglycerol (DAG) from the cleavage of phosphatidylinositol 4,5-bisphosphate (Hunyady and Catt, 2006) . The second messenger IP 3 binds to the calcium channel receptor IP 3 R present at the surface of the endoplasmic reticulum, thus liberating Ca 21 into the cytosol. G protein-coupled receptor kinases phosphorylate the receptor, leading to barrestin recruitment and functional uncoupling of G protein signaling. The AT 1 receptor also activates the G protein G 12 (Ushio-Fukai et al., 1998; Gohla et al., 2000; Sagara et al., 2007; Suzuki et al., 2009) . It is known that G 12, through the regulation of RhoGEF proteins, leads to the activation of RhoA/Rho kinase and cytoskeleton reorganization (Siehler, 2009) . The AT 1 receptor also activates extracellular signal-regulated kinases (ERK) 1 and 2 (Tian et al., 1998; Wei et al., 2003) . ERK1/2 activation by the AT 1 receptor is complex and can be mediated by protein kinase C (PKC; G protein-dependent) or by epidermal growth factor receptor (EGFR) transactivation (G protein-independent) (Luttrell, 2002; Miura et al., 2004) . Recent evidence has demonstrated that different ligands for a GPCR can stabilize the receptor under distinct conformations that promote the activation of some signaling pathways over others (Kenakin, 1995; Galandrin et al., 2007; Shonberg et al., 2014) . This phenomenon is referred to as ligand bias or functional selectivity. Biased ligands have been proposed to stabilize receptor conformations that are distinct from those induced by unbiased ligands and selectively change the propensity of GPCR coupling to various effectors, leading to different signaling outcomes. Several biased agonists have been recently described for numerous GPCRs, and such ligands show much therapeutic promise, which could translate to compounds having less off-target effects (Rominger et al., 2014; van der Westhuizen et al., 2014) .
The goal of the present study was to better comprehend the molecular basis underlying AT 1 receptor functional selectivity. Early structure-activity relationship studies using assays measuring rabbit aorta strip contraction and rat blood pressure have shown that position 8 of AngII is essential for ligand activity, whereas position 4 is critical for ligand affinity, as well as for ligand activity (Regoli et al., 1974) . Position 1 of AngII analogs is often substituted with sarcosine (N-methylglycine), which allows the peptides to resist aminopeptidase degradation. Angiotensin III (AngIII), also known as AngII (2-8), is an endogenous AngII peptide where the aspartic acid at position 1 is removed by aminopeptidase degradation. The ligand [Sar 1 Ile 4 Ile 8 ]AngII, which is unable to signal via the G q pathway, is able to selectively recruit barrestin (Wei et al., 2003) . Based on these observations, the goal of the study was to ascertain the impact of positions 1, 4, and 8 of AngII on the signaling profiles of the AT 1 receptor and thus gain some insight into whether these molecular determinants of AngII are involved in conferring the property of functional selectivity toward the AT 1 receptor. We therefore synthesized and investigated a series of peptide analogs containing amino acid substitutions at positions 1, 4, and 8 and determined their signaling profiles toward six different signaling pathways.
Materials and Methods
All reagents were from Sigma-Aldrich Canada Ltd. (Oakville, ON, Canada) unless otherwise indicated. Culture media, trypsin, fetal bovine serum, penicillin, and streptomycin were from Wisent (St. Bruno, QC, Canada). OPTI-MEM and RNAiMAX were from Invitrogen Canada Inc. (Burlington, ON, Canada). Polyethyleneimine (PEI) was from Polysciences (Warrington, PA). All small interfering RNAs (siRNAs) were from Sigma-Aldrich (St. Louis, MO). Antibodies against PKCz and PKCi were from Cell Signaling Technology (Whitby, ON, Canada). Peroxidaseconjugated donkey anti-rabbit IgG was from GE Healthcare (Little Chalfont Buckinghamshire, UK). Western Lightning Chemiluminescence Reagent Plus was from PerkinElmer (Waltham, MA). [ 125 I]AngII (specific radioactivity ∼1000 Ci/mmol) was prepared with Iodo-GEN (Perbio Science, Erembodegem, Belgium) as reported previously.
Constructs. The cDNA clone for the human AT 1 receptor was provided by Dr. Sylvain Meloche (University of Montréal, Montreal, QC, Canada). The AT 1 -GFP10 construct was built by inserting the GFP10 sequence at the C-terminus of the AT 1 construct, joined by the linker GSAGT, using the In-Fusion PCR cloning system (Clontech Laboratories, Mountain View, CA) as recommended by the manufacturer. The Renilla luciferase (RLuc)-barrestin1, RLuc-barrestin2, Ga12-RLuc, Gb1, and Gg1-GFP10 constructs were provided by Dr. Michel Bouvier (University of Montréal). All constructs were confirmed by automated DNA sequencing by alignment with multiAlin (Corpet, 1988) .
Cell Culture and Transfection. Human embryonic kidney (HEK) 293 cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 100 IU/ml penicillin, and 100 mg/ml streptomycin at 37°C in a humidified 5% CO 2 atmosphere. HEK293 cells stably expressing the AT 1 receptor were maintained in medium containing 0.5 mg/ml G418. For barrestin recruitment assays, HEK293 cells (3 ☓ 10 6 cells) were transiently transfected with 8700 ng of AT 1 -GFP10 and either 300 ng of RLuc-barrestin1 or 300 ng of RLucbarrestin2 using linear polyethyleneimine (1 mg/ml) (PEI:DNA ratio 4: 1). For G 12 activation assays, HEK293 cells (3 ☓ 10 6 cells) were transiently cotransfected with the following constructs: 3000 ng of AT 1 receptor, 600 ng Ga12-RLuc, 3000 ng Gg1-GFP10, and 1800 ng Gb1, using linear polyethyleneimine (PEI:DNA ratio 4:1). For siRNA transfection, HEK293 cells stably expressing the AT 1 receptor were seeded in a 96-well plate (50,000 cells/well), and each well was transfected with 1 pmol of the indicated siRNA using RNAiMAX (0.3 ml).
Binding Experiments. For binding experiments, broken cells were gently scraped into washing buffer [25 mM Tris-HCl (pH 7.4), 100 mM NaCl, 5 mM MgCl 2 ], centrifuged at 2500g for 15 minutes at 4°C, and resuspended in binding buffer [25 mM Tris-HCl (pH 7.4), 100 mM NaCl, 5 mM MgCl 2 , 0.1% bovine serum albumin, 0.01% bacitracin, 0.01% soybean trypsin inhibitor]. Dose displacement experiments were performed by incubating broken cells (20-40 mg of protein) for 1 hour at room temperature with 0.8 nM [
125 I]AngII as tracer and increasing concentrations of AngII. Bound radioactivity was separated from free ligand by filtration through GF/C filters presoaked for at least 3 hours in binding buffer. Receptor-bound radioactivity was evaluated by g counting. Results are presented as means 6 S.D. The K d values in the displacement studies were determined from the IC 50 values using the Cheng-Prusoff equation.
G q Signaling. G q signaling was evaluated by the measurement of inositol 1-phosphate (IP 1 ) production using the IP-One assay (Cisbio Bioassays, Bedford, MA). Necessary dilutions of each analog were prepared in stimulation buffer (10 mM Hepes, 1 mM CaCl 2 , 0.5 mM MgCl 2 , 4.2 mM KCl, 146 mM NaCl, 5.5 mM glucose, 50 mM LiCl, pH 7.4). HEK293 cells stably expressing the AT 1 receptor were washed with phosphate-buffered saline (PBS) at room temperature, then trypsinized and distributed at 15,000 cells/well (7 ml) in a white 384-well plate in stimulation buffer. Cells were stimulated at 37°C for 30 minutes with increasing concentrations of AngII or analogs. Cells were then lysed with the lysis buffer containing 3 ml of IP 1 coupled to the dye d2. After addition of 3 ml of anti-IP 1 cryptate terbium conjugate, cells were incubated for 1 hour at room temperature under agitation. Fluorescence resonance energy transfer signal was measured using an M1000 fluorescence plate reader (TECAN, Salzburg, Austria).
Bioluminescence Resonance Energy Transfer-Based Biosensor Assays. After 48 hours post-transfection, cells were washed with PBS and resuspended in stimulation buffer. For the barrestin recruitment assays, the proximity of fusion protein RLuc-barrestin to the reporter AT 1 -GFP10 was evaluated. Upon stimulation, RLucbarrestin was recruited to the AT 1 -GFP10 fusion protein, whereby the bioluminescence resonance energy transfer (BRET) signal was increased. For the G 12 activation assay, the biosensor measures the proximity of the fusion protein RLuc-Ga 12 to GFP10-Gg. Upon activation, both RLucGa 12 and GFP10-Gg move away from each other, which causes a decrease in the measured BRET. For both the barrestin recruitment assays and G 12 activation assay, cells transfected with the appropriate constructs were stimulated with the indicated ligands in 96-well white plates (50,000 cells/well) for 8 minutes, and then coelenterazine 400A was added at a final concentration of 5 mM. All BRET signals were measured using Functional Selectivity of AngII Analogs a TECAN M1000 fluorescence plate reader. The BRET ratio was calculated as the GFP10 emission over luminescence emission. Net BRET ratio was calculated by subtracting the BRET ratio under basal conditions from the BRET ratio upon maximal stimulation. All data were expressed as a percentage of maximal AngII response. ERK1/2 Activation Assay. ERK1/2 activation was measured using the ERK1/2 AlphaScreen Surefire kit (PerkinElmer). HEK293 cells stably expressing the AT 1 receptor were seeded into 96-well plates at a density of 125,000 cells/well. After 24 hours, cells were starved for at least 16 hours in phenol red-free media before stimulation. Where specified, protein kinase C inhibitor Go6983 [3-[1-[3-(dimethylamino) propyl]-5-methoxy-1H-indol-3-yl]-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione] (1 mM), EGFR tyrosine kinase inhibitor PD168393 [4-[(3-bromophenyl) amino]-6-acrylamidoquinazoline] (250 nM), or a combination of both inhibitors was added 30 minutes before stimulation. For time-course experiments, 100 nM AngII was added for the indicated times. For concentration-response experiments, cells were stimulated with increasing concentrations of indicated ligand. Cells were incubated at 37°C for either 2 minutes (PKC-ERK) or 5 minutes (EGFR-ERK), as determined by the peak responses obtained in the time-course assays. Stimulation of cells was terminated by the addition of lysis buffer to each well. The plate was then agitated at room temperature for 10 minutes, and 4 ml of lysate was transferred to 384-well ProxiPlates (PerkinElmer) and 5 ml of the assay reaction mix was added to each well (reaction buffer: activation buffer:donor beads:acceptor beads 5 120:40:1:1). The plate was then incubated in the dark at room temperature for 24 hours under agitation and the signal was measured with an EnSpire Alpha Plate Reader (PerkinElmer) using standard AlphaScreen settings. All data were expressed as a percentage of maximal AngII-induced ERK1/2 phosphorylation.
Western Blotting. HEK293 cells stably expressing the AT 1 receptor that had been transfected with siRNA for 48 hours as described earlier were washed with PBS and then solubilized with lysis buffer (1% Triton X-100, 150 mM NaCl, 50 mM Tris-HCl, 5 mM EDTA, pH 7.4) for 30 minutes at 4°C. Insoluble material was precipitated by centrifugation at 15,000g for 20 minutes at 4°C. Cell lysates (30 mg) were separated on an 8% SDS-PAGE gel and were transferred to a 0.2-mm polyvinylidene fluoride membrane in a 96 mM glycine, 10 mM Tris-base, and 20% methanol buffer for 60 minutes at 0.4 A at 4°C. The membranes were blocked for 1 hour at room temperature with Tris-buffered saline/Tween 20 (TBST) buffer (20 mM Tris-base, 150 mM NaCl, and 0.1% Tween 20) containing 5% (w/v) skim milk. They were then incubated for 2 hours at room temperature with rabbit anti-PKCz (1:1000) or rabbit anti-PKCi (1:250) in TBST supplemented with 5% skim milk. After three washes with TBST, the membranes were incubated with a peroxidase-conjugated donkey anti-rabbit IgG (1:2000) for 30 minutes at room temperature in TBST supplemented with 5% skim milk. They were then washed three times with TBST, and the immune complexes were visualized using Western Lightning Chemiluminescence Reagent Plus.
Data Analysis. Binding data were analyzed with Prism version 6.0 for Windows (GraphPad Software, San Diego, CA), using a onesite binding hyperbola nonlinear regression analysis. Transduction ratios and bias factors were calculated based on the method of Kenakin et al. (2012) , as described in detail by van der Westhuizen et al. (2014) . Transduction ratios [log(t/K A )] were first derived using the operational model equation in GraphPad Prism. The transduction ratio is an assessment of the effect (potency and efficacy) of a compound on receptor conformation and the subsequent ligandreceptor interaction with downstream effectors. To assess true ligand bias, system and observational bias which may be present owing to the different sensitivities of the assays used must be eliminated by comparing ligand activity at a given signaling pathway to that of a reference agonist. AngII, which yielded similar potencies and maximally activated all of the pathways, was the reference compound. By subtracting log(t/K A ) of AngII from the log(t/K A ) value of each analog for a given pathway, a within-pathway comparison was first established, yielding Dlog(t/K A ). Finally, between-pathway comparisons were achieved for a given ligand in the form of DDlog(t/K A ) and the bias factor. DDlog(t/K A ) was calculated by subtracting Dlog(t/K A ) values of one signaling pathway from the Dlog(t/K A ) of the signaling pathway to which it is compared. Bias factor values are the base 10 values of DDlog(t/KA) and are the actual bias factors.
Results
Binding Properties of AngII Peptide Analogs. We evaluated the binding properties of eight selected peptide analogs of AngII (Table 1) ]AngII also showed a high affinity with a good efficacy (Fig. 1B) , whereas AngIII had a good efficacy but a low affinity ( Table 2 . These results indicate that position 8 of AngII is critical for activating the G q pathway. These results also indicate that position 4 of AngII affects both the potency and the efficacy of the peptide in the activation of the G q pathway, whereas modifications at position 1 did not show any impact.
bArrestin Recruitment. To evaluate the capacity of the receptor to recruit and engage with either barrestin1 or barrestin2 following an 8-minute stimulation with each analog, a BRET-based barrestin recruitment assay was used. The AngII dose-response curve for barrestin1 recruitment revealed a maximal net BRET ratio of 0.085 (efficacy normalized to 100%) with an EC 50 of 6.1 nM ( Fig. 2A) , whereas that for barrestin2 recruitment revealed a maximal net BRET ratio of 0.106 (efficacy normalized to 100%) with an EC 50 of 4.6 nM (Fig.  3A) . [Sar 1 ]AngII showed a full efficacy and a high affinity for the recruitment of both barrestins (Figs. 2B and 3B ). AngIII showed a high efficacy and a low affinity for the recruitment of both barrestins (Table 2) ]AngII also showed a good efficacy but a very low affinity for the recruitment of both barrestins (Table 2) . ]AngIII was a partial agonist with a low affinity for the recruitment of both barrestins (Figs. 2F and 3F). All of these results are summarized in Table 2 . These results indicate that the analogs modified at position 8 of AngII are partial agonists for the recruitment of barrestins with relatively high potencies but with efficacies lower (∼50%) than that of AngII. The analogs modified at position 4 are also partial agonists for the recruitment of barrestins, although with relatively high efficacies (∼80% compared with AngII) and low potencies. Modifications at position 1 of AngII did not show any impact on the recruitment of barrestins.
G 12 Activation. The ability of the AT 1 receptor to engage with and activate the G 12 heterotrimer was evaluated using a BRET-based biosensor assay. The AngII dose-response curve shown in Fig. 4A revealed a net BRET ratio of 0.096 (Fig. 4B) showed a full efficacy and a high affinity, whereas AngIII (Table 2) (Fig. 4D) and [Ile 8 ]AngII (Fig. 4E ) were partial agonists with high affinities, whereas [Ile 8 ]AngIII (Fig. 4F) was a partial agonist with a low affinity for the activation of G 12 . All of these results are summarized in Table 2 . These results indicate that the analogs modified at position 8 of AngII are partial agonists for G 12 activation with relatively high potencies but with efficacies lower (∼40%) than that of AngII. The analogs modified at position 4 are also partial agonists for G 12 activation with efficacies lower (∼60%) than that of AngII and with low potencies. Modifications at position 1 of AngII did not show any impact on the activation of G 12 .
ERK Response. We evaluated the capacity of the selected AngII analogs to activate the ERK1/2 pathway by measuring ERK phosphorylation levels upon stimulation, a hallmark of ERK activity. Figure 5 shows that, under control conditions Functional Selectivity of AngII Analogs (circles), the addition of AngII increased ERK phosphorylation, which reached a maximal value at 5 minutes and then slowly declined toward the basal level. In the presence of the EGFR tyrosine kinase inhibitor PD168393 (triangles), the addition of AngII increased ERK phosphorylation, which reached a maximal value at 2 minutes and then slowly declined toward the basal level. In the presence of the PKC inhibitor Go6983 (squares), the addition of AngII increased ERK phosphorylation, which reached a maximal value at 5 minutes and then slowly declined toward the basal level. In the presence of both PD168393 and Go6983 (diamonds), the addition of AngII did not produce any measurable ERK phosphorylation. These results suggest that, in our experimental model, within the limits of our time course, AngII activates the ERK1/2 pathway via PKC following G q activation and via the transactivation of EGFR. Since the ERK1/2 response is completely abolished in the presence of both inhibitors, we reasoned that the ERK response in the presence of Go6983 was mediated by EGFR (pathway EGFR-ERK), whereas the ERK response in the presence of PD168393 was mediated by PKC (pathway PKC-ERK).
EGFR-Mediated ERK Response. To evaluate the EGFR-ERK pathway, HEK293 cells stably expressing the AT 1 receptor were treated with increasing concentrations of each analog for 5 minutes, in the presence of Go6983 ( Fig. 6 ; Table 3 ). The AngII dose-response curve shown in Fig. 6A shows a maximal response of 49,677 luminescence arbitrary units (efficacy normalized to 100%) with an EC 50 of 2.8 nM.
[Sar 1 ]AngII (Fig. 6B) showed a high efficacy and a high affinity, whereas AngIII (Table 3) (Fig. 6D) , [Ile 8 ]AngII (Fig. 6E) , and [Ile 8 ]AngIII (Fig. 6F ) were partial agonists with relatively low affinities for the activation of the EGFR-ERK pathway. All of these results are summarized in Table 3 . These results indicate that the analogs modified at position 4 are partial agonists, although with very high efficacies (∼94%) for the EGFR-ERK pathway. Furthermore, [Sar 1   Ile   4 ]AngII showed a higher potency (∼10 times) in the EGFR-ERK pathway than the G q , G 12 , and barrestin pathways. The analogs modified at position 8 of AngII are partial agonists of the EGFR-ERK pathway, with relatively low potencies (∼10 times lower than that of AngII) and with low efficacies (∼30% of that of AngII). Modifications at position 1 of AngII had no major impact on the EGFR-ERK pathway. 
Functional Selectivity of AngII Analogs
PKC-Mediated ERK Response. To evaluate the PKC-ERK pathway, HEK293 cells stably expressing the AT 1 receptor were treated with increasing concentrations of each analog for 2 minutes, in the presence of PD168393 ( Fig. 7 ; Table 3 ). The AngII dose-response curve shown in Fig. 7A shows a maximal response of 58,391 luminescence arbitrary units (efficacy normalized to 100%) with an EC 50 of 1.2 nM.
[Sar 1 ]AngII (Fig. 7B) showed a high efficacy and a high affinity, whereas AngIII (Table 3) ]AngII showed a higher potency (∼10 times) in the PKC-ERK pathway than the G q , G 12 , and barrestin pathways. The analogs modified at position 8 of AngII are partial agonists of the PKC-ERK pathway, with relatively low potencies (∼10 times lower than AngII) and low efficacies (∼30% that of AngII). Modifications at position 1 of AngII had no major impact on the PKC-ERK pathway.
Role (Tables 2 and 3) , which suggests the presence of signaling bias. To clearly establish whether an analog was biased toward one pathway over the others, the bias factors were determined for each analog and for all of the signaling pathways. Transduction ratios [log (t/K A )] were first derived using the operational model (Table 4) . The log(t/K A ) of the reference compound AngII was then subtracted from the log(t/K A ) value of each analog for a given pathway, yielding Dlog(t/K A ) as a within-pathway comparison for each signaling pathway. The Dlog(t/K A ) value is indicative of how well a given signaling pathway can be activated by a ligand, where a value of 0 indicates that a given ligand activates a pathway to the same degree as the reference compound, a positive value indicates that the ligand more strongly activates the signaling pathway than the reference compound, and an increasingly negative value indicates that the ligand poorly activates the signaling pathway, if at all. The Dlog(t/K A ) values of each analog calculated for every signaling pathway were represented on a radar plot, adapted from the "web of efficacy" (Evans et al., 2010; Zhou et al., 2013) (Fig. 9 ). This allowed a graphic representation highlighting to what extent each pathway can be activated (or not) by a given ligand. Ultimately, a between-pathway comparison was achieved for a given ligand in the form of DDlog(t/K A ), which is the actual bias factor (Tables 5 and 6 ).
The different analogs were partitioned into three groups, based on their functional selectivity profiles. The first group was composed of the analogs modified solely at position 1, [Sar 1 ]AngII and AngIII ( Fig. 9A ; Table 5 ). The analog [Sar 1 ]AngII showed Dlog(t/K A ) values ranging from 20.25 to 0.29, indicating that it is balanced relative to AngII (Fig. 9A) . These results suggest that position 1 of AngII is likely not an important molecular determinant for functional selectivity toward the AT 1 receptor. A second group of analogs included ]AngII (Fig. 9C) , [Ile 8 ]AngII (Fig. 9D) , and [Ile 8 ]AngIII (Fig. 9E) , which are modified at position 8. Figure 9C shows ]AngIII showed the same rank order of pathway activation as [Sar 1 Ile 8 ]AngII, but were less proficient at recruiting both barrestins and activating the G 12 pathway. Since none of the analogs in this group activated the G q pathway, no bias factor could be calculated. However, this in itself represents an obviously strong bias of these ligands for all other pathways over the G q pathway. Table 7 shows that the bias of [Sar 1
Ile 8 ]AngII toward barrestin2 over PKC-ERK was 2252-fold, whereas the bias of barrestin1 over PKC-ERK was 2147-fold. These represented the strongest biases found for AngII analogs 
Discussion
Functional selectivity is a relatively new concept, and its therapeutic potential is becoming more and more acknowledged (Rominger et al., 2014) . Ligand bias is the ability of certain ligands to stabilize distinct receptor-transducer pairs at the expense of others, leading to signal pathway selectivity. The goal of our study was to identify biased ligands of the AT 1 receptor and to better characterize the molecular determinants of AngII that underlie functional selectivity. A better understanding of the mechanisms leading to the recognition of distinct receptor-effector states by biased ligands should lead to the development of better therapeutics with less offtarget effects. For this study, 11 AngII peptide analogs together with the reference ligand AngII were selected to assess their functional selectivity profiles toward six different AT 1 receptor signaling outcomes. The pathways investigated were IP 1 production (as a reporter of G q activation), barrestin1 and barrestin2 recruitment, G 12 activation as assessed by a BRET biosensor assay, and the ERK1/2 activation via either PKC activation or EGFR activation. The ligands were chosen based on the previously characterized importance of positions 1, 4, and 8 for AngII activity, as demonstrated by previous structure-activity relationship studies (Regoli et al., 1974; Holloway et al., 2002) . We showed that the substitution of phenylalanine at position 8 of AngII for isoleucine abolishes G q signaling, whereas it maintains barrestin recruitment, G 12 , and ERK activation. The radar plot shown in Fig. 9 further indicates ]AngIII were antagonists for the G q pathway, and partial agonists with relatively high efficacies for barrestin recruitment and lower efficacies for the other pathways. It was known for a long time that AngII analogs containing an aliphatic residue at position 8 are antagonists of the G q pathway (Regoli et al., 1974; Miura et al., 1999 (Holloway et al., 2002; Ahn et al., 2004a) and recruit barrestin (Ahn et al., 2004b; Zimmerman et al., 2012 (Violin et al., 2010) . These results suggest that the molecular determinants present at position 8 of AngII contribute to AT 1 receptor functional selectivity, whereby G q activation is abolished, whereas the G 12 and barrestin pathways are maintained and ERK activity is strongly decreased.
Of particular interest, we found that [Sar 1
Ile 8 ]AngII, despite being unable to generate a G q -dependent response, was still able to activate ERK in an atypical PKC-dependent manner. It was previously shown that PKCz plays a role in AT 1 receptor ERK activation in vascular smooth muscle cells (Liao et al., 1997; Zhao et al., 2005; Kim et al., 2009) . These results support a role for both atypical PKC isoforms PKCi and PKCz in AT 1 receptor signaling that may have previously been underestimated.
We showed that the substitution of aspartate at position 1 for sarcosine ([Sar 1 ]AngII) or its removal (AngIII) had very little impact on the capacity of the AT 1 receptor to signal through the different pathways tested ( Fig. 9A ; Table 5 ). It has been long known that sarcosine at position 1 of AngII peptides confers resistance to aminopeptidase degradation in vivo (Hall et al., 1974) . Substitution at position 1 of AngII was seen to have little or no impact on smooth muscle contraction (an assay dependent on G q activation) (Hall et al., 1974) , inositol phosphates production (Holloway et al., 2002) , or total ERK activation (Miura et al., 2004 Ile 4 ]AngII are full agonists for PKCdependent and EGFR-dependent ERK activity, but partial agonists for the G 12 , barrestin, and G q pathways. Although the substitution of Tyr 4 for Ile 4 decreased the potency for activation of all of the pathways, this decrease was markedly less for the ERK pathway. This modification at position 4 appears to stabilize a receptor conformation that preferentially interacts with the effectors of the ERK pathway. To our knowledge, we are the first to evaluate and compare the impact of position 4 of AngII on different signaling pathways using a single model. We are also the first to evaluate the impact of position 4 on G 12 activation. It was previously shown that [Sar 1 Ile 4 ]AngII is a partial agonist of the G q pathway in CHO-K1 cells (Miura et al., 2004) . Substitution at position 4 was also shown to decrease AngII potency and efficacy in smooth muscle contraction assays (Regoli et al., 1974; Samanen et al., 1989) . A previous report indicated that substitutions at position 4 of AngII had very little impact on ERK activation in CHO-K1 cells (Holloway et al., 2002) . These results suggest that the molecular determinants present at position 4 of AngII contribute to AT 1 receptor functional selectivity, whereby ERK activity is maintained while the G 12, G q , and barrestin pathways are negatively impacted.
In conclusion, the purpose of our study was to establish the impact of positions 1, 4, and 8 of AngII on different signaling pathways downstream of the AT 1 receptor, and thus gain some insight into whether these molecular determinants of AngII were involved in conferring functional selectivity. Our study reveals that position 1 of AngII does not confer functional selectivity, whereas position 4 confers a bias toward ERK signaling over G q signaling, and that position 8 confers a bias toward barrestin recruitment over ERK activation and G q signaling.
